Covid-19 roundup: Pfiz­er, BioN­Tech seek au­tho­riza­tion of vac­cine for 5- to 11-year-olds; Fin­land halts roll­out of Mod­er­na vac­cine in younger men — re­port

Pfiz­er and BioN­Tech have of­fi­cial­ly asked the FDA to au­tho­rize their Covid-19 vac­cine for emer­gency use in chil­dren be­tween the ages of 5 and 11 years old, the phar­ma an­nounced Thurs­day on Twit­ter.

The FDA’s Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee will meet on Oct. 26 to dis­cuss the sub­mis­sion. If ap­proved, the Covid-19 vac­cine would be the first avail­able to kids of this age group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER